Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2018 1
2019 1
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Cannabis and cannabinoids.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-182. Med Lett Drugs Ther. 2019. PMID: 31770357 Review. No abstract available.
Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA).
Lorusso V, Russo A, Giotta F, Codega P. Lorusso V, et al. Core Evid. 2020 Jul 27;15:21-29. doi: 10.2147/CE.S203634. eCollection 2020. Core Evid. 2020. PMID: 32802009 Free PMC article. Review.
In fact, this combination is actually widely used and recommended for CINV prophylaxis for highly emetogenic cisplatin-based adriamycin/cyclophosphamide (AC) and carboplatin-based regimens. NEPA (netupitant/palonosetron) is the only fixed combination antiemetic available a …
In fact, this combination is actually widely used and recommended for CINV prophylaxis for highly emetogenic cisplatin-based adriamycin/cycl …
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Shimomura K, Kazunori H, Iihara H, Ohno Y, Inada Y, Arioka H, Morita H, Hida N, Sugawara M, Katada C, Nawata S, Ishida H, Tsuboya A, Tsuda T, Yamaguchi T, Nakajima TE. Minatogawa H, et al. BMJ Open. 2020 Dec 17;10(12):e041737. doi: 10.1136/bmjopen-2020-041737. BMJ Open. 2020. PMID: 33334838 Free PMC article. Clinical Trial.
Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when combined with neurokinin-1 receptor antagonist (NK1-RA) and palonosetron (Palo) for patients receiving HEC regimen, DEX sparing was n …
Although our multicentre randomised double-blind comparative study verified non-inferiority of sparing DEX after day 2 of chemotherapy when …
Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer.
Fleishman SB, Mahajan D, Rosenwald V, Nugent AV, Mirzoyev T. Fleishman SB, et al. J Oncol Pract. 2012 May;8(3):136-40. doi: 10.1200/JOP.2010.000151. Epub 2011 Dec 20. J Oncol Pract. 2012. PMID: 22942805 Free PMC article.
Seven patients (11%) had a history of motion sickness; 13 of 28 women (46%) reported history of pregnancy-induced morning sickness. Palonosetron slightly but significantly reduced the occurrence of nausea. ...
Seven patients (11%) had a history of motion sickness; 13 of 28 women (46%) reported history of pregnancy-induced morning sickness. …